Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 15/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | UBE2M | P61081 | 2/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730569 | 0.80 | PPARG (0.54) | PPARGPPARDPPARAUBE2MDCUN1D1 | |
| SCHEMBL10447010 | 0.78 | PPARG (0.56) | PPARGPPARDPPARAUBE2MDCUN1D1 | |
| SCHEMBL9259746 | 0.78 | PPARG (0.66) | PPARGPPARDPPARAUBE2MDCUN1D1 | |
| Trifluoroacetic Acid SCHEMBL6731864 | 0.76 | PPARG (0.59) | PPARGPPARDPPARAUBE2MDCUN1D1 | |
| SCHEMBL9260551 | 0.73 | PPARG (0.67) | PPARGPPARDPPARA | |
| SCHEMBL6699061 | 0.71 | CCR5 (0.86) | CCR5 | |
| SCHEMBL9270367 | 0.71 | UBE2M (0.52) | PPARGPPARDPPARAUBE2MDCUN1D1 | |
| SCHEMBL9270364 | 0.71 | UBE2M (0.52) | PPARGPPARDPPARAUBE2MDCUN1D1 | |
| SCHEMBL9265071 | 0.71 | PPARG (0.54) | PPARGPPARDPPARAUBE2MDCUN1D1 | |
| SCHEMBL27745186 | 0.70 | UBE2M (0.47) | PPARGPPARDPPARAUBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-01-08 | — | — | US | disclosed |
| EP-1289957-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | CCR5, CCR2, CCR1 | CCR5 1/4885PPARG 257/4885PPARD 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.